Table 1.
Characteristics of studies included in the meta-analysis.
| Authors | Area | Experimental Drugs | TMB Cutoff Value | Detection method | Sample size evaluable for TMB | Outcomes |
|---|---|---|---|---|---|---|
| Rizvi 2015 | America | Pembrolizumab | 178 | WES | 34 | PFS |
| Rizvi 2018 | America | Mono or combo | The 50th percentile of TMB | Targeted NGS | 240 | PFS |
| Hellmann 2018 | America | Nivolumab plus ipilimumab | 158 mutations | WES | 75 | PFS, ORR |
| Chae 2018 | America | Anti-PD-1/PD-L1 therapies | 15 | Targeted NGS | 34 | PFS, OS |
| Wang 2019 | Asian | Anti-PD-1/PD-L1 therapies | 6 | Targeted NGS | 50 | PFS, ORR |
| Ready 2019 | America | Nivolumab plus low-dose ipilimumab | 10 | Targeted NGS | 98 | PFS, ORR |
| Fang 2019 | Asian | Anti-PD-(L)1 monotherapy | NA | Targeted NGS | 75 | PFS, ORR |
| Chae 2019 | America | Anti-PD-1/PD-L1 therapies | NA | Targeted NGS | 20 | PFS, OS |
| Alborelli 2020 | Europe | Nivolumab/Pembrolizumab/ Atezolizumab/Nivolumab + Ipilimumab | 9mut/Mb | Targeted NGS | 76 | PFS, OS |
| Huang 2020 | Asian | PD-1/PD-L1 inhibitor monotherapy | 10mut/Mb | Targeted NGS | 34 | PFS, OS, ORR |
Combo = antiPD-(L)1+anti-cytotoxic T-cell lymphocyte-4 combination therapy, Mono = anti-programmed death 1 or anti-programmed death ligand 1 [anti-PD-(L)1] monotheism, mut = mutation, NA = not available, NGS = next-generation sequencing, ORR = objective response rate, OS = overall survival, PD-1/PD-L1 = programmed death 1/programmed death ligand 1, PFS = progression-free survival, TMB = tumor mutation burden, WES = whole exome sequencing.